CNTG Centogene NV: שווי פעילות לרווח לפני ריבית, מסים ופחת

This EV/EBITDA price chart for Centogene N.V. (CNTG) on the GURU.Markets platform captures the metric at . Centogene N.V. (CNTG) has established a comprehensive ecosystem for identifying rare pathologies by integrating diagnostics with analytics for the pharmaceutical industry. Leadership is driven by a massive genome archive and the application of neural networks. Meanwhile, molecular tests are conducted in-house, while data array storage is outsourced to reliable cloud providers.

This multiple compares the total enterprise value, including net debt, with operating profit before depreciation and amortization, determining the payback period for all assets. By analyzing the EV/EBITDA ratio of a company across a financial timeline, an investor identifies business overvaluation or hidden risks of model degradation. For Centogene N.V. (CNTG), such a metric is critical, as stable demand for genetics offsets market volatility, highlighting the resilience of this defensive medical asset.